Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.62 |
| ▸ | MAOB | P27338 | 2/20 | 0.62 |
| ▸ | CCR8 | P51685 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11312955 | 0.92 | BCHE (0.70) | BCHEMAOBCCR8KDM4EALDH1A1 | |
| SCHEMBL6264723 | 0.87 | BCHE (0.65) | BCHEMAOB | |
| SCHEMBL28412265 | 0.84 | BCHE (0.61) | BCHEMAOBALDH1A1 | |
| SCHEMBL27315592 | 0.83 | BCHE (0.61) | BCHEMAOBKDM4E | |
| SCHEMBL2893650 | 0.83 | BCHE (0.60) | BCHEMAOB | |
| SCHEMBL9685669 | 0.83 | BCHE (0.60) | BCHEMAOB | |
| SCHEMBL3206960 | 0.83 | BCHE (0.60) | BCHEMAOB | |
| SCHEMBL250507 | 0.83 | BCHE (0.61) | BCHEMAOBALDH1A1 | |
| SCHEMBL7458302 | 0.81 | BCHE (0.59) | BCHEMAOBKDM4E | |
| SCHEMBL8915069 | 0.81 | BCHE (0.57) | BCHEMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | TOPOTARGET SWITZERLAND SA (CH) | 2009-12-31 | — | — | US | disclosed |
| US-7276524-B2 | Pyridyl alkane acid amides as cytostatics and immunosuppressives | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| US-7276524-B2 | Pyridyl alkane acid amides as cytostatics and immunosuppressives | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | ASTELLAS PHARMA GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | ASTELLAS PHARMA GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-7241745-B2 | Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives | ASTELLAS PHARMA GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241745-B2 | Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives | ASTELLAS PHARMA GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | BIEDERMANN ELFI | 2007-06-21 | — | — | US | disclosed |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | BIEDERMANN ELFI | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | NFATC1, PDCD1, ACIN1 | BCHE 3147/4885MAOB 2552/4885CCR8 72/4885 |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | ALK, TYMP, PDCD1 | BCHE 3228/4885MAOB 1562/4885CCR8 150/4885 |
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | NAMPT, NNMT, NQO2 | BCHE 1537/4885MAOB 399/4885CCR8 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.